177 related articles for article (PubMed ID: 28165361)
1. Urine and Serum Metabolomics Analyses May Distinguish between Stages of Renal Cell Carcinoma.
Falegan OS; Ball MW; Shaykhutdinov RA; Pieroraio PM; Farshidfar F; Vogel HJ; Allaf ME; Hyndman ME
Metabolites; 2017 Feb; 7(1):. PubMed ID: 28165361
[TBL] [Abstract][Full Text] [Related]
2. Urinary Metabolomics Validates Metabolic Differentiation Between Renal Cell Carcinoma Stages and Reveals a Unique Metabolic Profile for Oncocytomas.
Falegan OS; Arnold Egloff SA; Zijlstra A; Hyndman ME; Vogel HJ
Metabolites; 2019 Jul; 9(8):. PubMed ID: 31344778
[TBL] [Abstract][Full Text] [Related]
3. Urine Metabolomics for Renal Cell Carcinoma (RCC) Prediction: Tryptophan Metabolism as an Important Pathway in RCC.
Liu X; Zhang M; Liu X; Sun H; Guo Z; Tang X; Wang Z; Li J; Li H; Sun W; Zhang Y
Front Oncol; 2019; 9():663. PubMed ID: 31380290
[TBL] [Abstract][Full Text] [Related]
4. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma.
Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y
Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842
[TBL] [Abstract][Full Text] [Related]
5. [Urinary metabolomics study of renal cell carcinoma based on gas chromatography-mass spectrometry].
Zhang L; Li L; Kong H; Zeng F
Nan Fang Yi Ke Da Xue Xue Bao; 2015 May; 35(5):763-6. PubMed ID: 26018279
[TBL] [Abstract][Full Text] [Related]
6. The value of blood oxygenation level-dependent (BOLD) MR imaging in differentiation of renal solid mass and grading of renal cell carcinoma (RCC): analysis based on the largest cross-sectional area versus the entire whole tumour.
Wu GY; Suo ST; Lu Q; Zhang J; Zhu WQ; Xu JR
PLoS One; 2015; 10(4):e0123431. PubMed ID: 25875306
[TBL] [Abstract][Full Text] [Related]
7. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
[TBL] [Abstract][Full Text] [Related]
8. Serum and urine analysis with gold nanoparticle-assisted laser desorption/ionization mass spectrometry for renal cell carcinoma metabolic biomarkers discovery.
Arendowski A; Ossoliński K; Ossolińska A; Ossoliński T; Nizioł J; Ruman T
Adv Med Sci; 2021 Sep; 66(2):326-335. PubMed ID: 34273747
[TBL] [Abstract][Full Text] [Related]
9. GC-MS metabolomics-based approach for the identification of a potential VOC-biomarker panel in the urine of renal cell carcinoma patients.
Monteiro M; Moreira N; Pinto J; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Carvalho M; Guedes de Pinho P
J Cell Mol Med; 2017 Sep; 21(9):2092-2105. PubMed ID: 28378454
[TBL] [Abstract][Full Text] [Related]
10. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
[TBL] [Abstract][Full Text] [Related]
11. SELDI-TOF-MS-based serum proteomic screening in combination with CT scan distinguishes renal cell carcinoma from benign renal tumors and healthy persons.
Xu G; Xiang CQ; Lu Y; Wang WJ; Kang XN; Liao P; Ding Q; Zhang YF
Technol Cancer Res Treat; 2009 Jun; 8(3):225-30. PubMed ID: 19445540
[TBL] [Abstract][Full Text] [Related]
12. Study on potential markers for diagnosis of renal cell carcinoma by serum untargeted metabolomics based on UPLC-MS/MS.
Wang J; Yang WY; Li XH; Xu B; Yang YW; Zhang B; Dai CM; Feng JF
Front Physiol; 2022; 13():996248. PubMed ID: 36523562
[No Abstract] [Full Text] [Related]
13. Evaluation of the prognostic significance of perirenal fat invasion and tumor size in patients with pT1-pT3a localized renal cell carcinoma in a comprehensive multicenter study of the CORONA project. Can we improve prognostic discrimination for patients with stage pT3a tumors?
Brookman-May SD; May M; Wolff I; Zigeuner R; Hutterer GC; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Truss M; Dalpiaz O; Feciche B; Figenshau RS; Madison K; Sánchez-Chapado M; Santiago Martin Mdel C; Salzano L; Lotrecchiano G; Zastrow S; Wirth M; Sountoulides P; Shariat S; Waidelich R; Stief C; Gunia S; ;
Eur Urol; 2015 May; 67(5):943-51. PubMed ID: 25684695
[TBL] [Abstract][Full Text] [Related]
14. [Proteomic analysis in combination with CT diagnosis to distinguish renal cell carcinoma from renal benign masses].
Xu G; Xiang CQ; Lu Y; Kang XN; Wang WJ; Liao P; Ding Q; Zhang YF
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(12):858-60. PubMed ID: 18756995
[TBL] [Abstract][Full Text] [Related]
15. Peripheral Blood Serum NMR Metabolomics Is a Powerful Tool to Discriminate Benign and Malignant Ovarian Tumors.
Nunes SC; Sousa J; Silva F; Silveira M; Guimarães A; Serpa J; Félix A; Gonçalves LG
Metabolites; 2023 Sep; 13(9):. PubMed ID: 37755269
[TBL] [Abstract][Full Text] [Related]
16. LC-MS-Based Plasma Metabolomics and Lipidomics Analyses for Differential Diagnosis of Bladder Cancer and Renal Cell Carcinoma.
Liu X; Zhang M; Cheng X; Liu X; Sun H; Guo Z; Li J; Tang X; Wang Z; Sun W; Zhang Y; Ji Z
Front Oncol; 2020; 10():717. PubMed ID: 32500026
[TBL] [Abstract][Full Text] [Related]
17. Are growth patterns on MRI in small (< 4 cm) solid renal masses useful for predicting benign histology?
Lim RS; McInnes MDF; Siddaiah M; Flood TA; Lavallee LT; Schieda N
Eur Radiol; 2018 Aug; 28(8):3115-3124. PubMed ID: 29492598
[TBL] [Abstract][Full Text] [Related]
18. Urine aquaporin 1 and perilipin 2 differentiate renal carcinomas from other imaged renal masses and bladder and prostate cancer.
Morrissey JJ; Mobley J; Figenshau RS; Vetter J; Bhayani S; Kharasch ED
Mayo Clin Proc; 2015 Jan; 90(1):35-42. PubMed ID: 25572193
[TBL] [Abstract][Full Text] [Related]
19. (1)H NMR metabonomic analysis in renal cell carcinoma: a possible diagnostic tool.
Zira AN; Theocharis SE; Mitropoulos D; Migdalis V; Mikros E
J Proteome Res; 2010 Aug; 9(8):4038-44. PubMed ID: 20527959
[TBL] [Abstract][Full Text] [Related]
20. A Unique Urinary Metabolic Feature for the Determination of Bladder Cancer, Prostate Cancer, and Renal Cell Carcinoma.
Lee S; Ku JY; Kang BJ; Kim KH; Ha HK; Kim S
Metabolites; 2021 Sep; 11(9):. PubMed ID: 34564407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
